Earnings Miss: Xvivo Perfusion AB (publ) Missed EPS And Analysts Are Revising Their Forecasts

There's been a major selloff in Xvivo Perfusion AB (publ) (STO:XVIVO) shares in the week since it released its quarterly report, with the stock down 30% to kr201. The results don't look great, especially considering that the analysts had been forecasting a profit and Xvivo Perfusion delivered a statutory loss of kr0.39 per share. Revenues of kr219m did beat expectations by 2.2% though. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the consensus forecast from Xvivo Perfusion's five analysts is for revenues of kr894.3m in 2025. This reflects a notable 8.7% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to dive 32% to kr2.40 in the same period. In the lead-up to this report, the analysts had been modelling revenues of kr961.2m and earnings per share (EPS) of kr2.44 in 2025. The consensus seems maybe a little more pessimistic, trimming their revenue forecasts after the latest results even though there was no change to its EPS estimates.

See our latest analysis for Xvivo Perfusion

The average price target was steady at kr406even though revenue estimates declined; likely suggesting the analysts place a higher value on earnings. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Xvivo Perfusion, with the most bullish analyst valuing it at kr496 and the most bearish at kr240 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that Xvivo Perfusion's revenue growth is expected to slow, with the forecast 12% annualised growth rate until the end of 2025 being well below the historical 33% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 17% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Xvivo Perfusion.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the negative side, they also downgraded their revenue estimates, and forecasts imply they will perform worse than the wider industry. Even so, earnings are more important to the intrinsic value of the business. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Xvivo Perfusion. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Xvivo Perfusion analysts - going out to 2027, and you can see them free on our platform here.

You should always think about risks though. Case in point, we've spotted 1 warning sign for Xvivo Perfusion you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.